Airborne transmission-mediated delivery of a live-attenuated influenza virus vector-based intranasal COVID-19 vaccine protects Syrian hamsters against SARS-CoV-2 challenge Authors: Yaode Chen, Limin Zhang, Congjie Chen, Lunzhi Yuan, Qiangyuan Han, Xijing Wang, Heming Chen, Xiangjie Chen, Ruotong Wu, Zeheng Li, Lingyu Han, Zhen Lu, Dongmei Wei, Ningshao Xia, Junyu Chen, Yixin Chen Published: 2025 ABSTRACT AbstractGiven their critical role in eliciting respiratory immunity, mucosal SARS-CoV-2 vaccines receive significant research attention. Our previous phase 1/2 trial revealed that aerosolized live-attenuated vectored influenza virus COVID-19 vaccine likely elicited specific cellular immunity and weak s-IgA responses in placebo recipients. Here, we demonstrated that viral vector vaccines undergo contact or airborne transmission in various animal models. Vaccines have difficulty spreading in the mouse model, but can effectively spread through the air in more sensitive ferrets. However, the virus transmission in ferrets can be effectively restricted by ventilation system. Furthermore, contact transmission of virus vaccine provided effective protection against lung pathology post-challenge with SARS-CoV-2 in hamsters. These findings suggest the potential to achieve herd immunity in specialized scenarios through airborne or contact transmission of dNS1-RBD, provided that appropriate delivery and control measures are implemented during the administration of live attenuated or viral vectored vaccines.Subject terms: Vaccines, Vaccines Introduction Despite the rapid development and clinical deployment of COVID-19 vaccines, the emergence of the SARS-CoV-2 JN.1, which is a descendant of BA.2.86, has posed a significant challenge globally1. This variant is remarkably efficient and highly contagious, demonstrating unprecedented and rapidly evolving immune escape2,3. As a result, there is an urgent need for broad-spectrum SARS-CoV-2 vaccines that employ different immune mechanisms and technical approaches to control the COVID-19 effectively. The development of mucosal SARS-CoV-2 vaccines has received considerable attention due to their advantages to induce protective immune responses in the respiratory tract4. However, the clinical challenges and limitations associated with intranasal SARS-CoV-2 vaccines have impeded progress, resulting in ongoing studies to address these issues5. We know that the key to the development of mucosal vaccines lies in how to deliver antigen proteins to the target respiratory tract and activate local immune responses6. Virus vectors, novel delivery techniques, mucosal adjuvants, and other methods are the focus of mucosal vaccine development. It is worth noting that currently, several mucosal COVID-19 vaccines in Phase III clinical trials or emergency use authorization are mainly based on virus vector constructs7. Virus vectors can effectively achieve tissue-specific delivery and induce more comprehensive immune responses. Therefore, viral vector vaccines or attenuated viral vaccines remain the most ideal vaccine strategy for mucosal immunization. When Oxford/AstraZeneca announced the Phase I clinical trial of the intranasal AZD1222, which induced neither a consistent mucosal antibody response nor a strong systemic response8. This failure might be due to the lack of specific receptors for the chimpanzee adenovirus vector used in the nasal cavity, making it difficult to establish effective infection and thus unable to induce effective immune responses. In contrast, the aerosolized adenovirus type-5 vector-based vaccine Ad5-nCoV from CanSino Biologics demonstrated a superior immune response through oral inhalation administration in preclinical trials compared to nasal spray administration9,10, which may be attributed to the differences in receptor distribution in the upper respiratory tract and oral cavity11. Notely, they utilize different adenovirus serotypes, spike sequence, formulations, and delivery devices (inhalers vs. sprayer), all of which may contribute to the different mucosal immune responses observed in clinical trials. Therefore, mucosal vaccines based on influenza virus vectors, due to their ability to recognize respiratory tract receptors, can serve as natural delivery vectors for respiratory viral vaccines with inherent advantages12,13. In conclusion, the development of mucosal vaccines and the understanding of respiratory immune mechanisms are still relatively limited. Thus, elucidating the delivery and establishment of mucosal immunity and defining protective immune markers has important theoretical and practical significance. In our previous study, we developed an intranasal COVID-19 vaccine named dNS1-RBD (Pneucolin), based on live-attenuated influenza viral vectors14,15. This vaccine has demonstrated a broad-spectrum protective effect against symptomatic Omicron infection in a randomized placebo-controlled Phase III clinical trial16,17. Consequently, it received emergency use approval in China on December 2, 2022. Notably, we observed that the administration of dNS1-RBD could generate vaccine virus aerosol, which potentially contributed to the specific cellular immune response and weak s-IgA antibody response observed in placebo recipients during the phase 1 and 2 clinical trials16. Interestingly, the extension trial confirmed that physical separation could prevent cross-contamination, as evidenced by environmental detection. This finding informs the clinical development of intranasal vaccines, particularly live-attenuated or viral-vectored candidates. The COVID-19 has highlighted controversies and unknowns about how respiratory pathogens spread between hosts. Previously, it was believed that respiratory pathogens spread among individuals through large droplets emitted during coughing and via contact with contaminated surfaces (fomites). Nevertheless, it is now recognized that various respiratory pathogens can be transmitted through small respiratory aerosols. These aerosols can remain suspended in the air and travel within air currents, infecting individuals who inhale them over short or long distances from the infected person18. Indeed, genetic engineering now enables the design of live viral vaccines and viral vector vaccines that are also potentially transmissible, which had been proved in clinical trials19,20. In several clinical trials and practical applications, live attenuated influenza vaccines have also frequently demonstrated virus shedding, but transmission incidents have been shown to be extremely rare21,22. Similarly, it has been reported that vaccine-derived poliovirus has caused infections in numerous individuals primarily due to the oral vaccine, which uses a live attenuated virus23. However, several questions remain unanswered regarding the limiting factors and assessment of immunological markers for aerosol transmission of live virus vaccines. It also remains uncertain whether intranasal vaccines transmitted via aerosols can effectively induce immune protection against SARS-CoV-2 challenge. To address these queries, our study demonstrated that nasal spray vaccines undergo transmission in various animal models, particularly for ferrets. Furthermore, we reported that contact transmission of dNS1-RBD provided effective protection against lung pathology post-challenge with SARS-CoV-2 in hamsters. These findings suggest the potential to achieve herd immunity in specialized scenarios through airborne or contact transmission of dNS1-RBD, provided that appropriate design and control measures are implemented during the administration of live attenuated or viral vectored vaccines. Results dNS1-RBD can transmit in mice and confers protection against lethal influenza virus challenge dNS1-RBD is a live attenuated influenza vaccine with a deletion in the NS1 gene. Compared to the wild-type virus, this vaccine replicates at low levels in the mouse model without causing weight loss (Fig. S1A, B), ensuring its safety while inducing both humoral and cellular immunity in mice. Based on transmission observed in earlier Phase II clinical trials, we hypothesized that the low-dose immunization effect was due to the spread of the dNS1-RBD in a closed environment. To validate this, we designed a transmission experiment in C57BL/6 mice (Fig. 1A). In this experiment, mice were evenly divided into two groups: sentinels group and a donors group. After immunization of the donors group with the dNS1-RBD, they were co-housed with the sentinels group in the same individually ventilated cage (IVC) under closed contact for 1 h, followed by ventilation (Fig. 1B). Through comparative analysis of two distinct mouse strains, we selected the C57BL/6 mouse model for subsequent experiments due to its heightened sensitivity in the contact transmission model (Fig. S1C, D). From the flow cytometry results of BALF collected on day 1 post-cohabitation, we observed significant activation of lymphocytes in donor mice compared to the control group. Notably, lymphocyte activation was also detected in the contact sentinels group. However, at 3 and 5 days post-cohabitation, enhanced lymphocyte activation was observed in the donors group, whereas only mild activation compared to the control group was detectable in the sentinels group (Fig. 1C). Seven days after contact transmission, SARS-CoV-2 S peptides-specific T cell conversion was assessed in isolated lung lymphocytes. While 100% (6/6) of the vaccine group exhibited robust T cell responses, only 33.3% (2/6) of the transmission group showed T cell conversion (Fig. 1D). At 14 days post-co-housing, mice were challenged with a lethal dose of H1/California/04/2009 influenza virus. The vaccine group showed no significant weight loss and provided 100% (5/5) protection against lethal infection. In contrast, the transmission group exhibited marked weight loss post-challenge but recovered by day 8, with 80% (4/5) of mice surviving the lethal challenge (Fig. 1E). Given that the mouse model is not highly susceptible to the vaccine strain, it was difficult to observe significant T cell immune activation in the sentinels group using direct contact methods. Therefore, we adopted an aerosolized vaccine approach, enhancing the concentration of vaccine aerosol in the air within a confined chamber. Mice were allowed to inhale aerosol particles of dNS1-RBD within a closed cage enclosure (Fig. 1F), mimicking the previous clinical setting. Lung tissues were collected from the inoculated and inhaled mice at various time points from 1 to 7 days post-infection (dpi). T cell conversion was examined to confirm infection among pulmonary lymphocytes and peripheral blood mononuclear cells (PBMCs) at 7 dpi. While mice inoculated with a high dose of dNS1-RBD exhibited significantly higher viral loads in lung tissue samples at 1, 3, 5, and 7 dpi compared to the inhaled groups and low dose vaccinated groups, some of the inhaled mice even showed undetectable infectious virus titers at 3, 5, and 7 dpi. Interestingly, the inhaled groups and low dose groups did not exhibit any statistically significant difference for the 100% of T cell conversion, though their local and systemic cellular response induced by dNS1-RBD were significantly lower compared to those from mice inoculated with a high dose (Fig. 1G, H). Overall, the sentinel mice in the contact transmission model demonstrated a minimal level of infective transmission, while the inhaled mice in the aerosol transmission model elicited a moderate cellular immune response, even though they showed a decreased level of infectious virus compared to direct intranasal administration. Contact transmission mediated delivery of influenza-vectored COVID-19 vaccine dNS1-RBD in mice. A Scheme of vaccination and challenge. Six-week-old female C57BL/6 mice were intranasally vaccinated with the dNS1-RBD. Bronchoalveolar lavage fluid (BALF) was collected from mice on days 1, 3, and 5 post-immunization for flow cytometry analysis. At 7 days post-immunization, lung lymphocytes were subjected to IFN-γ ELISPOT assay. Finally, the mice were challenged with the virus at 14 days post-vaccination. B Donor mice (C57BL/6, female, 6-week-old) were first inoculated with 1 × 106 PFU dNS1-RBD. Donor mice were paired and co-housed with mice (C57BL/6, female, 6-week-old) in cages for monitoring airborne transmission immediately. C Representative flow cytometry contour plots for Leukocyte in BALF at days 1, 3, 5 post vaccination. D IFN-γ ELISPOT assays for pulmonary lymphocytes from donors (n = 6) and sentinels (n = 6) at 1 week after co-housing were assessed under pre-stimulation of peptide pools covering the RBD of SARS-CoV-2. E body weight Changes of mice in the donors (n = 5) and sentinels (n = 5) following lethal challenge with A/California/04/2009 (H1N1) influenza virus (F) Illustration showing the vaccine were administered to mice by inhalation using a commercially available portable nebulizer. G Viral shedding of dNS1-RBD in mice. Two groups of mice immunized with a single-dose 1 × 106 (HD, high dose) and 1 × 105 PFU (LD, low dose) of the dNS1-RBD vaccines through the intranasal route were compared to the inhalation groups. The lung tissues of mice collected on days 1, 3, 5, and 7 were assayed by RT-PCR. H Lymphocytes in the peripheral blood and lung collected 7 days after immunization were further subjected to IFN-γ ELISPOT assays. Image created with BioRender.com, with permission (B, F). Dotted lines indicate the lower detection limit of the assay (D, G, H). Data are shown as mean ± SD. Two-tailed Student’s t-test (D) and ordinary one-way ANOVA multiple comparison (G, H) was used for intergroup statistical comparisons. Asterisks indicate statistical significance (****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant). dNS1-RBD can transmit between ferrets in a simulated enclosed environment Ferrets are susceptible to a wide range of human influenza virus isolates even without prior adaptation to the species24,25. They also develop a primarily upper respiratory tract infection, similar to humans. In order to characterize the transmissibility of dNS1-RBD in aerosol contamination in a clinical setting, we conducted additional studies using two airborne transmission models involving ferrets (Fig. 2A, D). In these models, two ferrets were housed in separate metal cages placed next to each other. The cages were divided by a customized, perforated metal divider that allowed for air circulation but preventing physical contact between the ferrets. Additionally, the neighboring metal cages had windows that could be opened or closed to regulate ventilation. Viral shedding, temperature, and body weight change of donors and sentinels ferrets in different transmission model were monitored from 1 to 6 dpi with a single-dose 1 × 107 PFU of the dNS1-RBD vaccines to donors groups. No significant body weight loss and temperature change were observed in donors and sentinel ferrets (Fig. S2A–D). Research on the influenza virus in ferrets suggests that the efficiency of transmission between ferrets is significantly inhibited in well-ventilated environments24. In this study, we also observed that no significant viral loads were detected in the nasal washes of ferrets from the sentinel ferrets in the ventilated environment (Fig. 2C). On the other hand, in environments with inadequate air circulation, the sentinel ferrets exhibited viral loads similar to the vaccine group 1 day after infection, and showed a trend of replication growth in the following days (Fig. 2F). From 3 to 6 dpi, the viral loads in the sentinel ferrets were significantly higher than those in the donor ferrets. In addition, serum samples were collected from ferrets before and 14 days after vaccination to analyze the influenza virus HA-specific antibody response and assess seroconversion. The results showed that in the well-ventilated environment, only the donor ferrets exhibited obvious antibody response (Fig. 2B). In contrast, in the poorly ventilated environment, consistent with the viral shedding results, both the ferrets in the donor and sentinel group exhibited seroconverted in serum binding assay after 14 days, and their antibody titers significantly increased (Fig. 2E). The NP-specific antibody results demonstrated a similar trend(Fig. S3A, B). The above results also validate our earlier findings in early clinical trials, which we found that subjects in the placebo group who were exposed to a small amount of aerosolized vaccine strain at the vaccination site also induced specific immune response that were not inferior to those in the vaccine group. Thus, aerosol delivery and immune responses induced by dNS1-RBD vaccines could be further confirmed in the transmission model of ferrets. However, this transmission phenomenon can be effectively restricted by opening windows for ventilation. Airborne transmission mediated delivery of influenza-vectored COVID-19 vaccine dNS1-RBD in ferrets. The ferrets (male: female = 1:1, n = 4) were used for further airborne transmission of dNS1-RBD. A, D Infected and naïve ferrets were placed in side-by-side metal cages with metal dividers that prevents physical contact while permitting air exchange. When wire-mesh windows opening was designed to improve air ventilation in above transmission model, opening windows were replaced by solid and sealed metal cages in below model. B, E The HA specific IgG levels of serum in two groups of ferrets. The serum samples were collected before and 14 days after inoculation from donor ferrets and sentinels ferrets in both transmission mode, and were further measured by ELISA for influenza HA specific antibodies response. C, F Viral shedding of donors and sentinels ferrets in different transmission model was analyzed for nasal washes collected at days 0,1, 2, 3, 4, 5, and 6 by RT-PCR after immunization with a single-dose 1 × 107 PFU of the dNS1-RBD vaccines to donors groups. Image created with BioRender.com, with permission (A, D). Dotted lines indicate the lower detection limit of the assay (C, F). Data are shown as mean ± SD. Two-way repeated-measures analysis of variance (ANOVA) with Dunnett’s multiple comparisons test (B, E) and two-tailed Student’s t-test (C, F) were used for intergroup statistical comparisons. Asterisks indicate statistical significance (****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant). dNS1-RBD can transmits in hamsters and protects them from lethal SARS-CoV-2 challenge To assess the ability of the sentinels from vaccinated donors of dNS1-RBD vaccines to mediate protection against SARS-CoV-2 virus, we conducted intranasal immunization with 1 × 105 PFU of dNS1-RBD vaccines in a golden Syrian hamster as donor hamsters. Considering previous studies that demonstrated influenza virus transmission mainly through contact in the hamster model, while airborne transmission efficiency was relatively limited26, in this study, we co-housed donor hamsters with naïve recipient hamsters as sentinels in a cage at 1 h post-inoculation (Fig. 3A). Lung tissue, nasal turbinate and trachea samples were collected from the donor and sentinel hamsters from 1, 3, 7 DPE to confirm infection (Fig. 3B, C, D). Respiratory tract infectious virus titers from dNS1-RBD vaccines exposed sentinels were detectable but significantly lower compared to those donor groups at 1 DPE, and then become undetectable at 3 and 7 DEP. After 7 days of contact transmission regimen, the donor and sentinel hamsters were challenged in the golden Syrian hamster inter-animal transmission model, which simulates the primary route of SARS-CoV-2 infection. For the prototype virus challenge, the control groups showed continuous body weight loss starting from 1 day post-infection (dpi), with a maximum weight loss of 8.5% at 7 dpi. In contrast, the vaccinated groups did not exhibit substantial weight changes, with mean weight loss of −0.7% for the donor groups and −2.2% for the sentinel groups (Fig. 3E). The viral loads in the lung tissue of donor and sentinel hamsters were slightly lower than those in the control groups at 5 and 7 dpi (Fig. 3F). At the end of the experiment, lung damage at 5 dpi and 7 dpi was quantitatively assessed using a comprehensive pathological scoring system and Hematoxylin and Eosin (H&E) staining examination. The control groups exhibited mild-to-moderate pulmonary consolidation, alveolar destruction, and diffuse inflammation. In contrast, both donor and sentinel hamsters were largely protected from lung damage caused by infection. They showed minimal focal histopathological changes in the lung lobes, and the severity scores of lung pathology were significantly lower in the vaccinated hamsters compared to the controls (Fig. 3G, Figs. S4A, B and S5). Altogether, dNS1-RBD-exposed sentinel hamsters were protected from SARS-CoV-2 challenge in the lungs, even though the absence of detectable infectious viral loads for sentinel hamsters. Contact transmission mediated delivery of influenza-vectored COVID-19 vaccine dNS1-RBD in hamster. Contact transmission mediated delivery of dNS1-RBD protects against lung pathology post challenge by SARS-CoV-2 in hamsters. A The donor hamsters were inoculated by 1 × 105 PFU of the dNS1-RBD vaccines, further paired and co-housed with sentinel hamsters (male: female = 1:1, n = 8) in cages with direct contact at 1 h post-inoculation. Infectious virus titers of lung tissue (B), nasal turbinate (C), and trachea samples (D) collected from donor and sentinel hamsters were measured by RT-PCR for up to 7 days post-exposure (male: female = 1:1, n = 4). After 1 week of transmission, the donor and sentinel hamsters were evaluated by contact-transmission challenge of SARS-CoV-2. Virus-carrying hamsters were pre-infected via inoculation of 1 × 104 TCID50 of SASR-CoV-2 virus through the intranasal route. Each donor was then transferred to a new cage and cohoused with four vaccinated above or control animals. One day after cohousing, donors were isolated from the cage, and the other hamsters were further observed. Weight changes (E), lung viral RNA levels (F) and pulmonary pathological scores (G) of hamsters challenged by SASR-CoV-2 virus were shown. The average weight loss of each group at 7 dpi is indicated as a colored number. The lung tissue was collected on day 5 after cohousing exposure for viral RNA and pathological analysis. Pulmonary pathological scores were determined based on the severity and percentage of injured areas for the whole lung tissue collected from the indicated animal. H Representative H&E-stained lung sections from tested hamsters collected on day 5 after cohousing exposure. Views of the whole lung lobes (4 independent sections) are presented in the above panel (scale bars, 2 mm), and the areas in the small black boxes are enlarged in the lower panel (scale bars, 100 μm). Image created with BioRender.com, with permission(A). Dotted lines indicate the lower detection limit of the assay (B–D, F). Data are shown as mean ± SD. Two-tailed Student’s t-test (B–D) and ordinary one-way ANOVA multiple comparison (E, F, G) were used for intergroup statistical comparisons. Asterisks indicate statistical significance (****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant). Discussion Current COVID-19 vaccines are highly effective in preventing severe disease; however, infection with newly emerging variants is not prevented, and virus loads can be high in vaccinated individuals. To control virus transmission and limit symptomatic infection, mucosal immunity at the site of virus entry is thought to be of paramount importance. Moreover, local cellular immunity and trained immunity in the respiratory tract are considered to be relatively broad-spectrum, which is beneficial for addressing challenges posed by SARS-CoV-2 variants15. In a previous publication, we described a nasally delivered live attenuated influenza vectored vaccine, dNS1-RBD, which targets the RBD of the SARS-CoV-2 prototype and has been approved for emergency use in China on December 2, 2022, under the name Pneucolin®. This vaccine candidate exhibited promising efficacy and a favorable safety profile, particularly in elderly individuals or those with underlying chronic diseases. It also conferred broad-spectrum protection against symptomatic COVID-19 caused by the SARS-CoV-2 Omicron variant in adults of all ages, regardless of underlying medical conditions. This protection was observed with both primary vaccination and heterologous booster doses in a Phase 3 clinical trial (ChiCTR2100051391)17. However, an intrinsic safety concern for live attenuated vaccine or viral vectored vaccine against a pandemic virus is the potential transmission of the vaccine virus. In principle, transmission of a vaccine virus may contribute to the establishment of herd immunity, but there is a possibility that an attenuated virus may directly or through reversion to a more virulent form cause illness among some at-risk individuals. We have previously demonstrated the genome stability of dNS1-RBD14. Here we found that the sentinel recipients could be exposed to droplets or aerosol containing vaccines virus through contact or airborne transmission in mice and ferrets. Consistent with clinical trials, the transmission of dNS1-RBD could be well controlled by reasonable measures. Another intriguing finding is that those exposed sentinel hamsters were largely protected from SARS-CoV-2 challenge. Thus, passive immunization via transmission of dNS1-RBD could be achieved. Transmission has the benefit of increasing herd immunity above that achieved by direct vaccination alone, but also increases the opportunity for vaccine evolution, which typically undermines vaccine utility. Different designs have different epidemiological consequences, but also experience different evolution. Approaches that integrate vaccine engineering with an understanding of evolution and epidemiology will reap the greatest benefit from vaccine transmission. Recent study had reported that either direct intranasal immunization or airborne transmission-mediated delivery of Nsp1-K164A/H165A in Syrian hamsters offers protection against heterologous challenge27. The different routes of mucosal administration being explored raise additional considerations around manufacturing, supply chain, safety, feasibility, acceptability, and cost-effectiveness that will factor into regulatory and policy decisions. In general, oral delivery options (pills, tablets, liquids) are the most straightforward to manufacture and deploy, followed by intranasal (droppers, sprayers) and then intratracheal (nebulizers, inhalers)28. In this study, the aerosol inhalation or transmission delivery proved to induce detectable T cell response, and further confer protection in challenge hamster models via contact transmission. Previous studies had showed that the dNS1-RBD induced moderate systemic IgG and mucosal IgA responses in mice, with robust tissue-resident memory T cells and trained immunity across the respiratory tract. However, in the hamster transmission model without proper immune detected methods, only a small amount of dNS1-RBD vaccines was detected in the sentinel hamster respiratory tract, but it still showed a nice protective effect. We guessed that the protective effects induced through contact transmission could be dependent on training the immune cells and structural cells in the respiratory tract, remodeling the immune microenvironment, and carrying out certain immunoregulatory effects after the heterologous challenge. This maintains the balance of the immune system and respiratory tissue and attenuates immune-induced tissue injury by only a small amount of live dNS1-RBD. Future research is warranted to explore the advantages of aerosol inhaled delivery through the nasal route for the dNS1-RBD vaccine. Nonetheless, while our study provides valuable insights into the efficacy of this vaccine, it is important to note that the extrapolation of the induction of immunity by live vaccines in rodent animal models to humans has inevitable limitations. Many efforts at intranasal vaccine development have been abandoned because of failure to repeat preclinical success in phase I trials, a common finding, often the result of inadequate understanding of differences in the human mucosal immune system from those of small animal models. It has already been noted above that nasopharyngeal immune anatomy differs between mice and humans5. In order to characterize the transmissibility of dNS1-RBD, ferrets were conducted and evaluated here, which are susceptible to a wide range of human influenza virus like human. Most intriguingly, the ferrets exposed to a small amount of aerosolized vaccine strain could be infected by dNS1-RBD effectively and induced a similar level of HA-specific antibody response, which also suggested the potential of aerosol inhaled immunization for nasal dNS1-RBD vaccine. The lack of validated correlates of protection for respiratory mucosal protection has implications for clinical research, as well as regulatory and policy considerations. In the previous study, the immune response to LAIVs, FluMist@, has found to be multifaceted and does not necessarily involve a serum antibody response29. In general, the induction of the production of mucosal antibodies and a local T cell response by LAIVs was similar to those induced by dNS1-RBD in adults. Unlike traditional intramuscular vaccines that mainly induce humoral immune responses and can establish known immune-bridging indicators, the large and expensive Phase 3 trials were needed to show clinical efficacy for dNS1-RBD. And there was more uncertainty about which mucosal immune markers are clinically meaningful for passive immunization via transmission of live attenuated or viral vectored vaccines. Therefore, additional immune correlate studies in humans are clearly critical for mucosal immunology. Based on the findings of this study and previous knowledge, we suggest that when applied in mucosal vaccine design for live attenuated vaccines, the administration methods, clinical protocols, and immune correlating indicators should need further analysis and exploration. The risks and benefits of administering an infectious and live attenuated vaccine must be balanced. In conclusion, our findings contribute to the ongoing efforts to develop effective vaccines against SARS-CoV-2 and possibly other mucosal respiratory viruses. Methods Cell cultures and viruses All cell lines were obtained from American type culture collection (ATCC). Human embryonic kidney cells (293T), African green monkey kidney epithelial cells (Vero E6), and Madin-Darby canine kidney cells (MDCK) were maintained in DMEM-high glucose (Sigma Aldrich) supplemented with 10% low-endotoxin FBS (Cegrogen Biotech) and penicillin-streptomycin. Generation and passage of dNS1-RBD viruses Eight pHW2000 plasmids containing the DelNS1 segment and the other seven influenza virus genomic segments, together with an NS1 expression plasmid, pCX-CA04-NS1-Flag, which was derived from the parental influenza virus A/California/04/2009 (H1N1) (GenBank No. MN371610.1-371617.1), were transfected into 293T cells and incubated overnight at 37 °C. The DNA mixture was removed, and Opti-MEM supplemented with 1 μg/mL 6-(1-tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin (Sigma, St. Louis, USA) was added. Viral supernatant was collected 72 h later, designated dNS1-RBD passage 0 virus, and was subsequently passaged in MDCK cells at 33 °C. The supernatant was harvested 48 h post-transfection when most of the cells showed signs of cytopathic effect (CPE). Infectious virus titers (plaque-forming unit (PFU)/mL) were determined by plaque assay on MDCK cells. Plaque assay for dNS1-RBD viruses Viruses were 10-fold serially diluted, added to confluent MDCK cells in 6-well plates, and then incubated at 37 °C for 1 h. The supernatant was removed, and the cells were washed twice with PBS and then overlaid with 1% minimum essential medium (MEM) agarose containing 1 μg/mL TPCK-treated trypsin. The plates were incubated at 33 °C for 72 h and then fixed with 4% PBS-buffered formaldehyde solution for at least 1 h. Plaques were visualized by staining with 1% crystal violet solution. Vaccine formulation The vaccine dNS1-RBD was generated as previously study and further prepared on a large scale at Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China. After rounds of passage and amplification with the cell factory based on the MDCK cell line, the viruses were further purified through a process step by step, including ultrafiltration, size-exclusion chromatography, nuclease treatment, and then ion-exchange chromatography to confirm the exclusion of exogenous factors. Purified virions were then mixed with virus protectant, which contained carbohydrates, amino acids, and human albumin, etc., and were preserved at −15 °C. Based on the ELISA results using a sandwich assay with anti-RBD monoclonal antibodies on both sides (Wantai, Beijing, China) and plaque assay results, serial passages 1–10 of purified vaccines were confirmed to be stable under current vaccine manufacturing conditions. The purified vaccines were further used in this study for comprehensive evaluation. Immunization and transmission of mice For contact transmission modes, C57BL/6 mice (female, 6-week-old, n = 6) were immunized intranasally with 50 μL of 2 × 106 PFU/mL of the vaccine strain per dose prepared as indicated above under isoflurane anesthesia. After inoculation, donor mice were then paired and co-housed with sentinel mice in cages for monitoring airborne transmission. Then, BALF was collected on days 1, 3, and 6. Pulmonary lymphocytes were collected on day 7 after inoculation for the IFN-γ ELISPOT assay. Mice were anesthetized under isoflurane prior to vaccinations. Lung collection was performed following euthanasia by CO2. Immunization and transmission of ferrets The ferrets (male: female = 1:1, n = 4) were used for airborne transmission of dNS1-RBD. Donor ferrets were inoculated with 1 × 107 PFU of the dNS1-RBD vaccines at first with a sample volume of 500 μl through the left and right nostrils. After immunization, infected ferrets and naïve (sentinel) ferrets were paired and placed in side-by-side metal cages with metal dividers, respectively. In ventilated mode, wire-mesh windows were opened at each side of the cage. In the closed model, the two windows are covered with curtains to prevent ventilation. Viral shedding, temperature, and body weight change of donors and sentinels ferrets in different transmission model were monitored from 1 to 6 dpi. Ferrets were sedated by intramuscular injection of ketamine/xylazine (17.9 and 3.6 mg/kg bodyweight), prior to vaccinations. Serum samples were collected from ferrets before and 14 days after vaccination. Nasal washes were obtained using 2 ml PBS under anesthetized. Immunization and infection of hamsters Donor hamsters (male: female = 1:1, 8 animals in each group) received 100 μL with 1 × 106 PFU/mL of vaccine strain per dose via the intranasal route. At 1 h post-inoculation, donor hamsters were co-housed with naïve recipient hamsters (male: female = 1:1, 8 animals in each group) in a cage. Lung tissue, nasal turbinate, and trachea samples were collected from the donor and sentinel hamsters from 1, 3, and 7 days post-exposure (DPE). At the indicated time after vaccination, the hamsters were further evaluated by direct contact challenge of SARS-CoV-2. The prototype-like virus AP8 (hCoV-19/China/AP8/2020; GISAID accession number: EPI_ISL_1655937) used in this study was passaged on Vero cells (#CCL-81, ATCC). Virus-carrying hamsters (donors) were pre-infected via inoculation of 1 × 104 TCID50 of SARS-CoV-2 through the intranasal route. Each donor was transferred to a new cage and cohoused with four vaccinated or control animals. One day after cohousing, the donors were isolated from the cage, and the other hamsters were further observed. The hamsters were fed a daily food amount of 7 g per 100 g of body weight. The weight changes and typical symptoms (piloerection, hunched back, and abdominal respiration) in hamsters were recorded daily after virus inoculation or contact. Hamsters were sacrificed for tissue pathological and virological analyses on days 5 and 7 after virus challenge. The virus challenge studies were performed in an animal biosafety level 3 (ABSL-3) facility. Hamsters were anesthetized under isoflurane prior to vaccinations and virus challenge. Lung tissue, nasal turbinate, and trachea samples were collected following euthanasia by CO2. Influenza virus challenge In influenza virus challenge studies, C57BL/6 mice (5 animals in each group) were inoculated with a lethal dose of various subtypes of influenza virus via the intranasal route. In brief, 14 days after one dose of dNS1-RBD, mice were further anesthetized under isoflurane and challenge with 2.5 × 104 of A/California/04/2009(H1N1) influenza virus, which was adapted to the mouse model. The mice were observed daily for mortality and morbidity, and body weight was measured up to 14 days after infection. Twenty-five percent weight loss was used as a humane endpoint for the challenge. Any mice reaching that endpoint were euthanized. The virus challenge studies were performed in an animal biosafety level 2 (ABSL-2) facility. Collection of BALF and flow cytometry The lungs of mice were laved with 0.9 mL of cold PBS containing 2 mM EDTA and 2% fetal bovine serum (FBS). The BALF was then centrifuged at 400 g for 10 min at 4 °C. The cell pellet was resuspended in RPMI 1640 medium. Cells from bronchoalveolar lavage fluid (BALF) were stained with BV786-conjugated anti-CD45 antibody (Invitrogen, USA) on ice for 30 min. The stained cells were analyzed using the BD LSRFORTESSA X-20 flow cytometry system (BD Biosciences). Data were analyzed using FlowJo X 10.0.7r2. Anti-HA IgG measurements HA-specific antibody titers in serum samples collected from immunized animals with the vaccine were determined by indirect ELISA. Ninety-six-well microtiter plates were coated with 100 ng of purified HA protein of influenza A virus A/California/04/2009 (H1N1) derived from Xiamen Wantai Biological Pharmacy Enterprise Co. at 4 °C overnight and blocked with 2% BSA for 2 h at 37 °C. Diluted sera (1:100) were successively diluted in a 2-fold series and applied to each well for 1 h at 37 °C, followed by incubation with goat anti-ferrets antibodies conjugated with HRP for 1 h at 37 °C after 3 washes. The plate was developed using TMB, followed by the addition of 2 M H2SO4 to stop the reaction, and read at 450/630 nm by an ELISA plate reader for final data acquisition. ELISPOT assay ELISPOT assays were performed using mouse IFN-γ ELISPOT plates (DAKEWE, Shenzhen, China). Ninety-six-well ELISPOT plates pre-coated with capture antibody were blocked with RPMI-1640 for 10 min at room temperature. Briefly, a total of 106 cells per well from lung tissues of C57BL/6 mouse immunized with 50 μL of 1 × 106 PFU/mL of vaccine were plated into each well and stimulated for 20 h with pooled peptides of RBD of wild type SARS-CoV-2 (15-mer peptide with 11 amino acids overlap, cover the RBD305-547, Genscript). The spots were developed based on the manufacturer’s instructions. PBS and cell stimulation cocktails from the kit were used as negative and positive controls, respectively. Spots were scanned and quantified by an ImmunoSpot CTL reader. Spot-forming units (SFUs) per million cells were calculated by subtracting the negative control wells. SARS-CoV-2 and dNS1-RBD RNA quantification Viral RNA levels in the tissues of challenged animals were detected by quantitative RT-PCR. Briefly, for quantification of viral levels and gene expression after challenge or passage experiments, RNA was extracted from homogenized organs or cultured cells using a QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Hamster tissue samples were homogenized by TissueLyser II (Qiagen, Hilden, Germany) in 1 mL of PBS. Subsequently, viral RNA quantification was conducted using a SARS-CoV-2 RT-PCR Kit (Wantai, Beijing, China) by measuring the copy numbers of the N gene. Quantification of dNS1-RBD replication was measured with primers targeting M mRNA. SARS-CoV-2 titration assay Live virus titers in homogenized lung tissues and cell cultures were measured by the standard TCID50 method in Vero E6 cells seeded in 96-well plates. In brief, the samples were serially diluted, added to the 96-well plates, and incubated with the Vero E6 cells for 1 h. Three days after incubation, the cytopathic effects were observed and used to calculate the viral titers. Histopathology The lung tissues from challenged hamsters were fixed with 10% formalin for 48 h, embedded in paraffin, and sectioned. Next, the fixed lung sections were subjected to hematoxylin and eosin (H&E) staining. Whole-slide images of the lung sections were captured by an EVOS M7000 Images System (Thermo Fisher). The standards for pathological score of lung tissues in this study are adapted and optimized from a recent study of SARS-CoV-2 infection in a hamster model30. In brief, H&E staining result of the whole lung tissue was analyzed for its severity of pathological change. The pathological score includes: (a) Alveolar septum thickening and consolidation; (b) Hemorrhage, exudation, pulmonary edema, and mucous; (c) Recruitment and infiltration of inflammatory immune cells. For each issue, score related to the severity: 0 indicates no pathological change was observed, 1 indicates moderate pathological change, 2 indicates mild pathological change, 3 indicates severe pathological change, and 4 indicates very severe pathological change. In conclusion, scores of such three issues were added as the comprehensive lung pathological score of a lung tissue. Statistical analysis Statistical significance was assigned when P values were <0.05 using GraphPad Prism 8.0. The bars in this study represent the mean ± SD. The number of animals and independent experiments that were performed is indicated in the figure legends. Student’s t-test (two groups) or one-way analysis of variance (ANOVA) (three or more groups) was used for comparison of normally distributed continuous variables. Two-way repeated-measures ANOVA was adopted for repeated data comparison. Ethics statements All animals involved in this study were housed and cared for in an Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility. All experimental procedures with mice, ferrets, and hamsters were conducted according to Chinese animal use guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) of Xiamen University (XMULAC20230240). The hamster studies were performed in an animal biosafety level 3 (ABSL-3) laboratory affiliated to the State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong. Supplementary information Supplementary Information Acknowledgements Diagrams were created with BioRender.com. This work was supported by the National Program on Key Research Project of China (2023YFC2307800 and 2023YFC3042900), the National Natural Science Foundation of China (82041038, 32000649), Natural Science Foundation of Fujian Province (2021J02006), Science and Technology Project of Xiamen City (2022CXY0108), the Fundamental Research Funds for the Central Universities (20720220006), the Open Research Fund of State Key Laboratory of Vaccines for Infectious Diseases (2024SKLVDkf02), and Research Fund of Xiang An Biomedicine Laboratory (2024XAKJ0101002). Author contributions J.C., N.X., and Y.C. conceived the project and designed the experiments; Y.C., L.Z., C.C., L.H., Z.L., and D.W. prepared the dNS1-RBD vaccines, performed viral characterization experiments; Y.C., L.Z., C.C., L.Y., X.W., R.W., Z.L., and Q.H. participated in the mice, ferrets and hamsters challenges; L.Y., H.C., and X.C. tested the RNA quantification and histopathology; Y.C., L.Z., and J.C analyzed data; Y.C., L.Z., J.C., and Y.C. wrote the manuscript; Y.C., L.Z., N.X., J.C., and Y.C. participated in the discussion and interpretation of the results. All authors reviewed and approved the paper. AI-assisted technologies were used in the writing process for revision and modification. Data availability The data supporting the findings of this study are available within the article and the main figures or its supplementary materials. Raw data used to generate plots are available from the corresponding authors upon reasonable request. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Yaode Chen, Limin Zhang, Congjie Chen, Lunzhi Yuan. Contributor Information Junyu Chen, Email: JunyuChen@xmu.edu.cn. Yixin Chen, Email: yxchen2008@xmu.edu.cn. Supplementary information The online version contains supplementary material available at 10.1038/s41541-025-01332-5. References Associated Data Supplementary Materials Supplementary Information Data Availability Statement The data supporting the findings of this study are available within the article and the main figures or its supplementary materials. Raw data used to generate plots are available from the corresponding authors upon reasonable request.